(Q28477237)

English

Why drug safety should not take a back seat to efficacy

scientific article

In more languages

edit

Statements

0 references

0 references

Why drug safety should not take a back seat to efficacy (English)

0 references

1

Virginia Barbour

0 references

Jocalyn Clark

object named as

Jocalyn Clark

series ordinal

2

0 references

Emma Veitch

series ordinal

6

object named as

Emma Veitch

0 references

Melissa L Norton

series ordinal

4

object named as

Melissa Norton

0 references

author name string

Susan Jones

series ordinal

3

0 references

Paul Simpson

series ordinal

5

0 references

language of work or name

English

0 references

publication date

September 2011

0 references

published in

PLOS MEDICINE

0 references

volume

8

0 references

issue

9

0 references

page(s)

e1001097

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

27 September 2011

1 reference

stated in

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181229

retrieved

19 March 2017

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181229

retrieved

19 March 2017

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181229

retrieved

29 September 2017

Drug-review deadlines and safety problems

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3181229

retrieved

29 September 2017

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001097

retrieved

21 January 2018

Clinical Trial Registration — Looking Back and Moving Ahead

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001097

retrieved

21 January 2018

Postmarketing studies of drug safety

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21984875

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1371/JOURNAL.PMED.1001097

0 references

PMC publication ID

3181229

0 references

PubMed publication ID

21984875

0 references

ResearchGate publication ID

221699247

0 references

(Q28477237)

Why drug safety should not take a back seat to efficacy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)